Mortality in elderly dementia patients treated with risperidone

Journal of Clinical Psychopharmacology

Volumn 26, Issue 6, 2006, Pages 566-570

  Haupt, Martin ^a,d,e,f,g   Cruz Jentoft, Alfonso ^b   Jeste, Dilip ^c,e  

^a Neuro Centrum Dusseldorf   (Germany)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JANSSEN CILAG GMBH   (Germany)

^e Novartis ^*

^f PFIZER INC   (United States)

^g Lundbeck GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FUROSEMIDE; RISPERIDONE;

ARTICLE; BEHAVIOR DISORDER; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEMENTIA; DRUG EFFICACY; DRUG WITHDRAWAL; HEART ARREST; HEART FAILURE; HUMAN; MENTAL DISEASE; META ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DEMENTIA; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 33751083857     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000239796.21826.39     Document Type: Article

References (28)

1. Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry. 2001;16:39-44.
2. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708-714.
3. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;228:1475-1483.
4. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioural changes in Alzheimer's disease. Neurology. 1996;46:130-135.
5. Brodaty H, Draper BM, Low LF. Behavioural and psychological symptoms of dementia: a seven-tiered model of service delivery. Med J Aust. 2003;178:231-234.
6. Haupt M, Kurz A, Janner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord. 2000;11:147-152.
7. Jeste DV, Finkel AI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29-34.
8. Schneider LS, Katz IR, Park S, et al. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry. 2003;11:414-425.
9. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
10. American Geriatrics Society, American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in U.S. nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc. 2003;51:1287-1298.
11. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ. 2004;329:75-79.
12. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210.
13. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269-1270.
14. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170:1395.
15. Abilify [package insert]. Bristol-Myers Squibb Company, London, UK and Otsuka America Pharmaceutical, Inc, Tokyo, Japan; 2005.
16. US Food and Drug Administration. Center for Drug Evaluation and Research. Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 11, 2005.
17. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
18. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341.
19. Deberdt WM, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13:722-730.
20. Katz IR, Jeste DV, Mintzer JE. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107-115.
21. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia. Neurology. 1999;53:946-955.
22. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry. 2003;64:134-143.
23. Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer's disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006;14:280-291.
24. Chaves PH, Kuller LH, O'Leary DH, et al. Subclinical cardiovascular disease in older adults: insights from the Cardiovascular Health Study. Am J Geriatr Cardiol. 2004;13:137-151.
25. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9:361-381.
26. De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005;107:497-508.
27. Suh GH, Shah A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr. 2005;17:429-441.
28. Nasrallah HA, Nasrallah AT. Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. Am J Geriatr Psychiatry. 2004;12:437-439.